Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Interest & Investment Income (2016 - 2017)

Heron Therapeutics filings provide 6 years of Interest & Investment Income readings, the most recent being $3.4 million for Q4 2017.

  • On a quarterly basis, Interest & Investment Income rose 123.07% to $3.4 million in Q4 2017 year-over-year; TTM through Dec 2017 was $3.6 million, a 873.44% increase, with the full-year FY2025 number at $1.9 million, down 45.13% from a year prior.
  • Interest & Investment Income hit $3.4 million in Q4 2017 for Heron Therapeutics, up from -$552000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $3.4 million in Q4 2017 to a low of -$775000.0 in Q3 2016.
  • Median Interest & Investment Income over the past 3 years was -$204000.0 (2013), compared with a mean of $227000.0.
  • The widest YoY moves for Interest & Investment Income: up 123.07% in 2017, down 365.0% in 2017.
  • Heron Therapeutics' Interest & Investment Income stood at -$209000.0 in 2013, then skyrocketed by 823.92% to $1.5 million in 2016, then skyrocketed by 123.07% to $3.4 million in 2017.
  • The last three reported values for Interest & Investment Income were $3.4 million (Q4 2017), -$552000.0 (Q3 2017), and -$744000.0 (Q2 2017) per Business Quant data.